Supply Chain Derisking: The Case For US-India Partnering Amid China Clout

With just 14% of active pharmaceutical ingredients estimated to be made in the US and China’s overall dominance in the space, a new study points to the pressing need for the US to address bottlenecks in the supply chain and proposes a string of approaches to partner with India in its de-risking efforts.

Partnering for supply chain resilience • Source: Shutterstock

The COVID-19 pandemic highlighted the risks of concentrated supply chains and the impact these can have on medicines security across countries, with ongoing geopolitical tensions and wars only further complicating present-day dynamics.

A new study by the IQVIA Institute for Human Data Science has now put forth a range of policy and...

More from Supply Chain

More from Business